Recent data relating to the mechanisms of disorders of the CNS

Chronic progressive neurodegenerative diseases such as Parkinson's disease (PD),
Alzheimer's disease (AD), Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS) are becoming increasingly more prevalent, which may be related to the aging of the population. The significance of neurological diseases is highlighted by the fact that brain disorders have been stated to be responsible for around 35% of the total burden of all diseases in Europe 1 . Migraine, a common primary headache disorder with an overall prevalence of 16% in the adult population, is listed among the 20 most important causes of disability worldwide [2] [3] . The increasing prevalence, the high socioeconomic impact and the limited therapeutic possibilities have generated considerable research interest in recent decades.
Although the various neurodegenerative disorders present distinct clinical symptoms, their pathomechanisms share several features. A long line of evidence indicates that neuroinflammation, mitochondrial disturbances, glutamate (Glu) excitotoxicity and oxidative stress are involved to various extents in the neurodegenerative process [4] [5] [6] . Neuroinflammation is an important mechanism that has been implicated in the pathomechanism of many neurodegenerative diseases [7] [8] [9] and the normal aging process 10 . Activation of the microglia and astrocytes has been detected in neurodegenerative disorders such as PD and HD, and this process may even influence the release of Glu [11] [12] [13] [14] . Mitochondrial disturbances result in an energy deficit and the production of free radicals, which results in disruption of the membrane potential and in oxidative stress. Free radicals may lead to protein misfolding or lipid peroxidation, thereby damaging neuronal cells. As the brain has high oxygen and energy demands, it is especially sensitive to energy impairment and oxidative damage. A mitochondrial dysfunction and oxidative damage have been described in AD, PD and ALS [15] [16] [17] [18] .
Another key mechanism in the neurodegenerative process is Glu-mediated excitotoxicity. Glu, the main excitatory neurotransmitter in the brain, has a crucial role in a number of Recent findings strengthen the linkage between the endocannabinoid system (ECS) and the kynurenine pathway (KP) [19] [20] . There has been growing interest in the potential of the therapeutic palette of cannabis and cannabinoid-based chemicals in neurological conditions in recent decades. A role of the ECS has been implicated in motor control, cognition, mood, feeding behaviour and pain [21] [22] [23] [24] . Alterations in the ECS and/or the benefits of therapy have been considered in PD [25] [26] [27] [28] , HD [29] [30] [31] , migraine 20 , pain [32] [33] and multiple sclerosis (MS) [34] [35] . The preclinical and clinical research into the value of cannabinoids in movement disorders has been reviewed by Kluger et al. 36 . There is an important risk of abuse in the case of cannabisbased drugs 37 , but the enhanced endogenous brain kynurenic acid (KYNA) levels could probably mitigate this 19 .
The emerging evidence links chronic Toxoplasma gondii infections to disorders of the CNS.
This obligate intracellular protozoan parasite affects 30-50% of the total human population, the frequency increasing with age [38] [39] . Many publications have linked this infection with AD 40 , PD [41] [42] , schizophrenia 43 , migraine [44] [45] , headache [46] [47] [48] , autism 48 , autoimmune diseases 49 , MS 50 and other diseases. There is evidence that toxoplasmosis has an impact on the KP. The infection causes induction of the expression of indoleamine 2,3-dioxigenase (IDO), the increased formation of L-kynurenine (L-KYN), a decreased level of tryptophan (Trp), and an increased level of dopamine, thereby stimulating tachyzoites proliferation [51] [52] . Moreover, T.
gondii infection is associated with persistent (life-long) neuroinflammation, and this abnormality is associated with an increased production of Glu, mitochondrial damage, and oxidative stress 53 . Investigations of the role of such infections in modulation of the KP in different neurological disorders began with schizophrenia 54 . This field promises interesting findings in the future.
The role of the KP has been extensively investigated in immunoregulation, in which the enzyme IDO is of outstanding importance. IDO causes Trp depletion and is responsible for the production of kynurenines, which occurs at the beginning of the enzymatic pathway. IDO is expressed in various immune cells: monocytes, macrophages and microglia [55] [56] . The activity of IDO can be enhanced by interferons and lipopolysaccharides. Interferon-γ is considered to be the main activator of IDO. The IDO activation leads to elevations in the levels of the various kynurenines, among them KYNA. IDO counteracts the proliferation of reactive lymphocytes, and can therefore be an important regulator of immune activation. This give rise to a depletion of Trp, whereas quinolinic acid (QUIN) and 3-hydroxyanthranilic acid (3HAA) result in the selective apoptosis of Th1 cells [57] [58] . This function is considered to play a significant role as a negative feedback loop in the regulation of the immune response and may contribute to the development of immune tolerance [59] [60] [61] [62] . IDO-mediated T cell inhibition affects primarily the Th1 cells however, through the activation of regulatory T cells 56 this process may influence Th2 cell activation as well. 
The kynurenine metabolism
The scientific world has recently been demonstrating increasing interest in the therapeutic potential of the metabolites and enzymes of the main degradation pathway of the essential amino acid Trp. Trp is transported across the blood-brain barrier (BBB) with the assistance of the large neutral amino acid transporter 63 . In the human brain, 95% of the Trp is involved in the KP 64 (the remaining 5% participates in the serotonin pathway and the formation of proteins) (Figure 1 ). This metabolic route is responsible for the synthesis of nicotinamide adenine dinucleotide (NAD) and NAD phosphate, KYNA, xanthurenic acid (XA) and picolinic acid (PIC). The central compound of the KP is L-KYN, formed from Trp, the ratelimiting steps of its synthesis involving the enzymes IDO and tryptophan 2,3-dioxygenase (TDO). Most of the L-KYN (approximately 60%) is taken up from the blood 65 with the aid of the neutral amino acid carrier 66 , the remainder being generated locally in the CNS. After the synthesis of L-KYN, the cascade branches into three routes. The first possibility is the synthesis of KYNA from L-KYN through irreversible transamination by kynurenine aminotransferases (KATs). The other main branch of the cascade begins with the formation of the neurotoxic 3-hydroxykynurenine (3HK) through the action of kynurenine-3-monooxygenase (KMO), the third important enzyme in the KP. KMO is responsible for the neurotoxic branch of the cascade, the concentration of KYNA depending indirectly on its activity. Kynureninase converts 3HK to 3HAA. In the third route, kynureninase converts L-KYN to anthranilic acid, which further metabolize to 3HAA. Another neurotoxic metabolite in the route is QUIN, which is synthesized from 3HAA by 3HAA oxygenase (3HAO). QUIN is the precursor of NAD and NADP synthesis (Figure 1 ).
The infiltrating macrophages, activated microglia and neurons are capable of the complete enzymatic cascade within the CNS, whereas the astrocytes and oligodendrocytes lack IDO and KMO and are unable to produce the neurotoxic QUIN 67 . Most of the locally synthesized neuroprotective KYNA and PIC 68 is therefore generated in the astrocytes and neurons, while QUIN is synthesized by the infiltrating macrophages and microglia 69 .
The term kynurenines is the overall name for the metabolites of this pathway; most of them display neuroactive properties and three of them (KYNA, 3HK and QUIN) have key roles in certain CNS disorders.
Neuroactive kynurenine metabolites and their impact on receptors in the CNS
KYNA: The most characteristic feature of this metabolite is the broad-spectrum, competitive antagonism of all three ionotropic excitatory Glu receptors (the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), the kainate receptor and the NMDAR) at high micromolar concentrations (to approximately the same degree) 69 . It is most active at the NMDARs, after binding at the strychnine-insensitive glycine co-agonist site of the NMDAR complex 70 . NMDAR-mediated excitotoxicity and free radical production are involved in the pathology of many neurodegenerative disorders and the number of endogenous Glu receptor antagonists (similarly to the level of KYNA) is very low. Besides its main impact on the NMDAR complex, KYNA exerts weak antagonistic impacts on the AMPARs and kainate receptors too. However, its effect on the AMPARs depends on its concentration: at low concentrations (nanomolar to micromolar) it behaves as a facilitator, whereas at high concentrations (micromolar to millimolar) it behaves as an inhibitor [71] [72] . The α7 nicotinic acetylcholine receptors (nAChRs) are also important targets for KYNA, and under physiological conditions this has proved to be extremely determinative 73 . Its noncompetitive antagonistic impact results in reduced acetylcholine, dopamine and Glu Independently of its impact on the receptors, the in vitro and in vivo evidence confirms that KYNA has antioxidant and free radical scavenger properties 75 ; this broadens its neuroprotective features and focuses attention on the importance of KYNA-mediated neuroprotection.
A recent study with the model organism Caenorhabditis elegans suggested a new feature of KYNA: it is a nutritional cue that enables behavioural plasticity 76 . QUIN: The neurotoxic properties of QUIN have led to its being widely used in animal models of HD [77] [78] [79] . Its neurotoxic features 80 are a consequence of its weak, but specific competitive agonist action on the NMDAR subgroup including NR2A and NR2B 55, 81 . The NMDARs have brain region-specific locations. NMDARs which contain NR2C subunits are hindbrainspecific, while NMDARs with NR2B subunits are found predominantly in the forebrain. This results in regional selectivity, because QUIN binds with 10-fold lower activity to the hindbrain-specific NR2C subunits of the NMDARs as compared with the NR2B subunits 82 .
Apart from its activation on the NMDARs, it has a complex neurotoxic potential, including the enhancement of presynaptic Glu release [83] [84] , the inhibition of astrocytic Glu uptake 84 , depletion of the local antioxidant supply 85 , the generation of reactive oxygen intermediates 86 and the peroxidation of lipid molecules 81, 87 , which depends strictly on the amount of Fe . 3HK: The toxic features of this metabolite are independent of the NMDARs and are connected only to the production of free radicals 90 . Cultured striatal and cortical neurons treated with 3HK exhibited a reduced viability, irregular somata, and shrunken and reduced neuritic outgrowths [91] [92] ; this was prevented by the antioxidant catalase 93 . In contrast with neuronal cells [92] [93] , cultured glioma cells did not display susceptibility to 3HK [94] [95] . These data indicate that glial cells may tolerate the presence and toxic effect of 3HK much more easily than do neurons, in which 3HK is endogenously not present 96 . 3HK potentiates quinolinate, but not NMDA toxicity in the rat striatum 97 . Intrastriatal co-administration of 3HK and QUIN in subtoxic doses results in neuronal death in the striatum, which indicates that 3HK has neurodegenerative properties in the presence of QUIN 97 .
3HAA: Kynureninase converts 3HK to 3HAA. This metabolite undergoes auto-oxidation, during which highly reactive hydrogen peroxide and hydroxyl radicals are formed [98] [99] . Superoxide dismutase 1 enhances, whereas catalase abolishes these reactions 93, 99 . These findings are evidence that the detrimental effect of 3HAA is mediated by reactive oxygen species.
PIC: PIC is one of the metabolic products of the KP 100 . Besides KYNA, PIC displays antagonism towards the toxic action of QUIN, though the exact mechanism is unknown [101] [102] [103] .
In vitro studies suggest that it has an immunomodulatory character besides its antiviral, antimicrobial and antitumour effects, but the experimentally used concentrations in these studies were much higher than the reported endogenous concentration of PIC 104 . The large discrepancy between the endogenous and experimental PIC levels means that these observations may not be related to the natural physiological function of PIC.
XA: XA is formed from 3HK through the action of KATs. XA is closely related to KYNA structurally (the difference is merely a hydroxy group) ( Figure 1 ). It has been verified as a ligand of the endogenous Group II (mGlu2 and mGlu3) metabotropic Glu receptors 105 . These receptors and the metabolites of the KP have been implicated in the pathophysiology of schizophrenia. A recent study postulated that XA is probably the first potential endogenous allosteric agonist for the mGlu receptors 105 . It has also been demonstrated to exert an antiinflammatory effect through a reduction of interferon-γ 106 .
The kynurenine pathway and the immune system in aging
Alterations in the levels of the KP enzymes and compounds have been observed not only in neurological disorders [107] [108] [109] , but also in the aging process [109] [110] [111] [112] . If the KP metabolism is compared in older individuals and in young adults, upregulation of the Trp-KYN metabolism may be noted in the elderly 113 . Moreover, the activity of IDO in nonagenarians is markedly increased and predicts mortality 114 . Exploration of the relationship between the KP and aging through the use of animal models is a unique and useful technique, because the KP is conserved evolutionarily in insects, rodents and humans.
Drosophila melanogaster is an ideal animal model of the aging process 115 , because it is a cheap, fast-growing species in which many mutants have been described. In Drosophila, the genes of the KP are responsible for the colour of the eyes. The end-product of the KP pathway is the brown eye pigment experiments. An age-related increase was found in the level of KYNA in the human CSF 119 , and elevated levels of KYNA and QUIN in the rat brain [120] [121] .
Nevertheless, age-dependent alterations in the KP have been described not only in healthy animal models, but also in specific disease models, e.g. in the YAC128 mouse model of HD 109 and a C. elegans AD model 111 .
In summary, investigations of the KP are of considerable importance not only in diseases and in disease models, but also in aging models. Exploration of the differences between normal aging and neurodegenerative diseases may facilitate a better understanding of both processes.
The decline of the immune system with age can be detected in the increased susceptibility to infections, in the modest immune response after vaccination, in the growing number of cancer cases, and in the increased number of autoimmune and other chronic diseases characterized by a pro-inflammatory state among the elderly 10, [122] [123] [124] [125] . Both the innate 126 and the adaptive immune responses showed changes because of the aging process, but the adaptive response seems to be more affected 10 . This topic is summarized in Table 1 and has been well reviewed by Castelo-Branco and Soveral
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. Inflamm-aging 127 , the characteristic chronic low-grade inflammatory state observed in aged individuals has been implicated in the pathogenesis of many age-related diseases, such as AD [128] [129] . This process is characterized by increased levels of proinflammatory markers and cytokines and it should be taken into account when we speak about CNS disorders, which appear mostly in elderly populations. Increasing evidence has emerged of an association between PD and alterations in the KP (Table 3 ). Lower concentrations of KYN and KYNA were measured in the frontal cortex, putamen and SNPC of PD patients as compared with controls 132 . Additionally, the concentration of 3HK was elevated in the putamen and SNPC in the PD group 132 .
There are alterations in the KP in the two widely used animal models of PD [133] [134] [135] . The expression of KAT I in the substantia nigra of mice was decreased after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment 133 . Moreover, 1-methyl-4-phenylpyridinium and 3-nitropropionic acid diminished the cortical synthesis of KYNA in rats via interference with the KATs 135 . Alterations in the KP in the periphery have also been demonstrated in PD. The increased activity of KAT II in correlation with the elevated KYNA level in the red blood cells may relate to a possible protective process 136 . The importance of the KP was supported by experiments in which the inhibition of KMO increased the KYNA level, thereby not only preventing neurotoxic damage of the striatal dopaminergic neurons, but also alleviating the dyskinesia caused by dopamine replacement [137] [138] . However, despite increasing evidence of the linkage of KP and PD, genetic evidence is not yet available 130 . Both in vitro 139 and in vivo 137, [140] [141] experiments indicate therapeutic possibilities through elevated levels of KYNA.
Huntington's disease
HD is an autosomal dominantly inherited neurodegenerative disease caused by trinucleotide expansion (CAG-glutamine) within exon 1 of the huntingtin protein (htt-located 4p16.3). This leads to neuronal cell death in the brain, and especially in the striatum and cortex, which causes motor, cognitive and psychiatric symptoms. The age at disease onset correlates inversely with the length of the CAG expansion. Genetic modifiers and the environment play critical roles in patients who have 36-39 repeats 142 . Especially in these individuals, but certainly in those who exhibit symptoms (>40 repeats), manipulation of the KP may be a beneficial tool.
In the early phase of the disease, increased QUIN and 3HK and moderately increased KYNA concentrations have been measured in the striatum, associated with decreased KYNA/QUIN and KYNA/3HK ratios 55, 143 ( Table 3) . These results were strengthened by a full-length mutant huntingtin mouse model 144 . In the late stages, the KYNA levels are decreased in the cortex, striatum and CSF [145] [146] , while that of 3HK is increased in the brain 147 . Decreased KAT activity has been demonstrated in the striatum 145, 148 , and elevated 3HAO activity in the brain . This is supported not only by neuroanatomical observations, but also by the therapeutic effect of the low-affinity noncompetitive NMDA receptor antagonist, memantine.
The relationship between AD and the KP is also indicated by other observed alterations 55 ( Table 3 ). The KP is up-regulated in the AD brain; the regulatory enzyme of the pathway, IDO, is abundant in AD as compared with controls, leading to increase in the excitotoxin QUIN 108 . Moreover, QUIN is co-localized in the cortex with phosphorylated tau 160 and induces tau phosphorylation in human primary neurons 160 . Alterations are also observed in the periphery; the serum level of 3HK was markedly increased in AD patients, but the Trp, KYNA, PIC and QUIN concentrations were similar to those in the controls 161 . The KYNA concentration was significantly decreased both in the plasma and in the red blood cells, but the levels of KYN and the activities of KAT I and KAT II remained unchanged 162 . In a mouse model of the disease, the IDO inhibitor coptisine ameliorated the cognitive impairment 163 .
Multiple sclerosis
MS, the most common chronic autoimmune/neurodegenerative demyelinating disorder of the CNS acording to Lucchinetti 164 , emerges mostly in young adults and affects 2.5 million people worldwide. In a recent study, the standardized prevalence was found to be 83.7/100,000 and the female:male ratio in the MS population in Csongrád County, Hungary was 3.08 165 . The clear role of a genetic predisposition has been suggested, together with unidentified environmental factors and autoimmune inflammatory mechanisms. The lifetime risk has been reported to be 1 in 400 166 , which makes MS potentially the most common cause of neurological disability in young adults.
The KP plays a pivotal role in regulating the balance between activation and inhibition of the immune system through the immunomodulatory effect of IDO 56 . The linkage between the kynurenine system and immunoregulation has been reviewed [55] [56] . IDO has immunosuppressive action, and IDO-KP can serve as a negative feedback loop for Th1 cells 56 , which can be important in MS therapy.
It may be presumed that not merely IDO plays a crucial role in MS, as QUIN and 3HK proved to be elevated in the more caudal regions of the spinal cords of the animals in experimental autoimmune encephalitis (EAE), an animal model of MS [167] [168] ( Table 3) .
Furthermore, the linkage of KP and MS and the therapeutic benefit of modulation of the cascade are strengthened by another EAE model study [169] [170] . In that work, the KP metabolite cinnabarinic acid (an endogenous agonist of the type-4 metabotropic Glu receptor) suppressed EAE in mice [169] [170] . Moreover, recent results indicated QUIN-induced oligodendrogliotoxicity in two cell lines 171 , which could be attenuated by specific KP enzyme inhibitors and anti-QUIN monoclonal antibodies. This could be very important in MS, where the pathological hallmark is irreversible demyelination.
The levels of KYNA in the CSF of relapsing-remitting MS (RRMS) patients were significantly lower during remission 172 . By contrast, the KYNA levels in the CSF were elevated during acute relapse 173 . A recent study not only investigated the KP metabolite levels from the CSF, but was also the first comprehensive analysis of CSF kynurenine metabolites in MS patients in different disease stages in relation to neurocognitive symptoms. At the group level, MS patients did not show any difference in the absolute levels of the KP metabolites (Trp, L-KYN, KYNA and QUIN) as compared with the control group, but the stratification of the data according to the disease course revealed that both absolute the QUIN levels and the QUIN/L-KYN ratio were increased in RRMS patients in relapse, the secondary progressive MS patients showed a tendency to lower Trp and KYNA concentrations, and the primary progressive cohort displayed increased levels of all metabolites (similarly to the inflammatory neurological disease controls) 129, 174 . The depressed patients demonstrated higher KYNA/Trp and L-KYN/Trp ratios (mainly due to low Trp levels) 129, 174 . There was no linkage between the pattern of KP metabolites in RRMS patients and the neurocognitive symptoms 129, 174 . The study concluded that the clinical disease activity and differences in disease courses are correlated with the changes in KP metabolites 129, 174 . In the periphery, elevated levels of KYNA and KAT I and KAT II activities have been reported in the plasma and erythrocytes 175 . These changes may indicate a compensatory protective mechanism against excitatory neurotoxic effects.
It is questionable whether activation of the KP in MS is beneficial or detrimental. It may be beneficial in the early stages, because IDO activation can downregulate T cell proliferation. In contrast, prolonged activation of the KP may lead to chronically elevated levels of QUIN and other neurotoxins produced by perivascular macrophages, thereby contributing to further neurological deficits 176 . In an animal model of MS, the activation of IDO ameliorated [177] [178] , while the inhibition of IDO exacerbated EAE 176, 179 , and anti-inflammatory metabolites of the KP ameliorated EAE 180 . The therapeutic aspects of the KP in MS and the role of the KP in the dialogue between the immune system and the CNS were well reviewed recently.
Amyotrophic lateral sclerosis
ALS is a rapidly progressive and fatal neurodegenerative disease with characteristic pathological features: degeneration of the upper (cortical) and lower (spinal and pontobulbar) motor neurons. Despite the fact that it is the most common motor neuron disease, ALS is rare.
Its mean incidence in Europe is 2.8/100,000, while its mean prevalence is 5.40/100,000 181 .
Only 5-10% of the cases are classified as familial, which mainly inherited in an autosomal dominant manner [182] [183] , the remaining 90% being sporadic Currently only one effective mode of therapy exists (Riluzole, an anti-Glu agent similar to KYNA), which slowed the progression and possibly improved the survival in patients with bulbar onset in a double-blind placebo-controlled clinical trial 183, 185 .
The role of Glu in ALS is not only supported by this therapeutic possibility; loss of a key Glu transporter (the Glu transporter-1 isoform responsible for keeping the extracellular Glu levels below neurotoxic), and increased extracellular Glu levels have also been described in both the sporadic and the familial form of ALS The linkage of the KP and ALS is additionally indicated by the alterations in the KP in ALS (Table 3) . Significantly increased levels of Trp, KYN and QUIN in the CSF and serum, and a decreased serum level of PIC have been measured in ALS samples, with enhanced microglial and neuronal IDO expression in the motor cortex and the spinal cord and elevated IDO activity in the CSF 188 . High KYNA levels were measured in the CSF in patients with a severe clinical status or with bulbar onset, whereas the serum KYNA levels were decreased in cases with a severe clinical status 189 . These changes are probably a part of the neuroprotective compensation. In vitro experiments with the NSC-34 cell line showed that KYNA may have anti-apoptotic features [190] [191] . An animal model of the disease revealed changes in zinc-binding capacity [192] [193] , and PIC could therefore be a neuroprotectant in ALS because of its zinc chelator property. These findings provide strong evidence of the involvement of the KP in ALS, therefore possibly opening the way for new therapeutic opportunities in this fatal disease.
Migraine
Migraine, the most common type of primary headache, is a multifactorial recurrent brain disorder 194 . Its cumulative incidence has been reported to be 43% in women and 18% in men 195 . In 75% of the cases, the age at onset is less than 35 years 195 . Because of its high frequency, its economic importance should not be underestimated, in view of the costs of treatment, the loss of worktime and the decrease in productivity. The electrophysiological hallmark of the disease is cortical spreading depression (CSD), an excitatory slowly progressing wave of depolarization accompanied by a long-lasting suppression of neuronal activity and excitability in the cortex of the brain 196 . CSD is assumed to be the neurological basis of the aura phenomenon 197 , which affects one-third of migrainers 198 . In the pathomechanism of migraine, genetic factors 199 , peripheral sensitization of the trigemino-vascular system (caused by the changed cerebral blood flow and sterile neurogenic inflammation) [200] [201] , central sensitization of the caudal trigeminal nucleus 202 , the activation of specific brain stem nuclei, called migraine generators (the dorsal raphe nucleus, the nucleus raphe magnus, the locus coeruleus and the periaqueductal grey matter) [203] [204] [205] and, not least, the development of CSD 206 are assumed. The common feature of these five processes is the role of Glu in each 207 and the importance of Glu in the pathomechanism is also indicated by the elevated Glu levels in the CSF during the attacks 208 , and in the plasma (without aura) and in the platelets (with aura) in the headache-free periods 209 , which may reflect persistent hyperexcitability 208 . Because of this common point, the therapeutic possibilities draw attention to the NMDA antagonist of the KP, KYNA. Elevated levels of KYNA or its analogues significantly attenuate the central sensitization of the caudal trigeminal nucleus [210] [211] and alleviate the activation of the migraine generators 212 and primary and secondary trigeminal nociceptive neurons [213] [214] ; moreover, KYNA inhibits CSD both in the cerebellum and in the neocortex 215 . L-KYN or a synthetic KYNA analogue was also able to decrease nitroglycerine-induced calcitoningene related peptide (CGRP) expression 211 . CGRP is one of the most investigated neuropeptides in research, especially because CGRP antagonists and monoclonal antibodies are of promise for the therapy of migraine [216] [217] [218] [219] . Although increased KYNA levels have been found in the rat brain after triggered CSD, this is presumably an adaptive response for neuroprotection 55, 207 . KYNA additionaly alleviates the nociception caused by formalin and capsaicin in animal models [220] [221] . The systemic administration of KYN attenuates the frequency of CSD in female rats, whereas in male rats this effect was observed only when probenecid was co-administered 222 . However, the administration of KYN with probenecid not only influences CSD, but also mitigates the central sensitization of the caudal trigeminal nucleus 210, 223 . After electrical stimulation of the trigeminal ganglia (migraine model), decreased KAT immunoreactivity was detected in the dural macrophages, Schwann cells and mast cells 55, 224 , which leads to a reduced production of KYNA. These results indicate that kynurenine metabolites can influence the brainstem structures involved in the pathogenesis of migraine, and KYNA and its analogues may serve as a novel and useful therapeutic approach.
Schizophrenia
Schizophrenia is a disorder characterized by psychiatric symptoms and a cognitive dysfunction. Its pathology involves biochemical alterations in Glu neurotransmission (hypoGlu-ergic hypothesis), which can cause secondarily altered dopamine homeostasis 225 . This Glu deficiency theory has been strengthened by genetic studies 226 .
Investigations of the KP in schizophrenia revealed increased KYNA levels in the CSF and in post-mortem tissues 225, [227] [228] [229] , whereas the level was lower in the blood of the patients 230 and in an animal model 231 ( Table 3 ). The KYNA level was elevated in the prefrontal cortex 225, 227 , where a reduced metabolic function has been at the focus of interest in schizophrenia studies.
Indeed, increased concentrations of this NMDAR antagonist can cause a hypo-Glu-ergic state in the brain [232] [233] . The increased KYNA levels may be caused by reduced levels of the enzymes responsible for the synthesis in the other branches of the pathway. The activities of the enzymes, and the protein and mRNA levels of 3HAO and KMO proved to be reduced in the prefrontal cortex region in post-mortem samples, while those of IDO, KAT and quinolinic acid phosphoribosyltransferase were normal [234] [235] . The 1q42-q44 chromosome region, where KMO is located, has been implicated in the disease aetiology [236] [237] . Another genetic study supported the role of KMO in schizophrenia, in which the rs1053230 single nucleotide polymorphism was found to be strongly associated with increased CSF KYNA concentrations 233 in both controls and patients, but another, larger study failed to establish a significant association of KMO and schizophrenia 238 . This contradiction could be due to the different populations. Aoyama et al. used only the clinical diagnosis and no other clinical parameters, and they collected Japanese samples from different geographical regions.
Interleukin-1B and IDO single nucleotide polymorphisms were studied together and a combination of alleles was associated with schizophrenia 239 . These results may indicate a slight genetic association and support the role of the KP in this disease.
In animal models of schizophrenia, elevated KYNA levels may be associated with cognitive deficits 69, 225 . The decrease of the extracellular Glu concentrations by KYNA was accompanied by the deteriorating performance of mice and rats in different cognitive tests, while the inhibition of KAT (which decreases the KYNA level) secondarily increases the release of Glu and improves the skills of the animals 225 .
In summary, investigation of the KP is important in schizophrenia, and might be important in the future in other psychiatric diseases too (bipolar disorder and autism) [240] [241] [242] . In contrast with the diseases described above, the decreased Glu and increased KYNA levels may contribute to the development of schizophrenia.
Possibilities for neuroprotection by modulating the kynurenine pathway
As discussed above, KYNA is a neuroprotective agent because of its broad-spectrum nonselective anti-Glu properties. Its neuroprotective action has been demonstrated against the neurotoxicity induced by kainate, ibotenate, QUIN or NMDA 243 . This metabolite of the KP is therefore of therapeutic potential, but unfortunately it has only a very limited ability to cross the BBB. For therapeutic exploitation, there are four main possibilities. One option is to use precursors of KYNA, L-KYN or its halogenated derivatives, which cross the BBB more readily (prodrug concept). A second possibility is to synthetize KYNA analogues which pass through the BBB more easily, but have at least the same neuroprotective effect as that of KYNA. A third option is to shift the KP towards the production of KYNA through the use of enzyme inhibitors. A fourth possibility is to make use of the innovations of nanotechnology, "packing the KYNA", which results in easier passage of the compound through the BBB (Figure 2 ).
Prodrug concept
Preclinical studies have verified the efficacy of pretreatment with the neuroprotective L-KYN [244] [245] , which proved more effective when co-administered with probenecid in different disease models: epilepsy 246 , migraine (L-KYN combined with probenecid and a novel synthetic KYNA derivative attenuated nitroglycerine-induced neuronal nitric oxide synthase in the rat caudal trigeminal nucleus [210] [211] ), PD 140 and AD 247 . Systemic L-KYN and probenecid administration displayed a protective effect against the behavioural and morphological alterations induced by toxic soluble amyloid beta (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) in the rat hippocampus 248 . However, the results of post-treatment were contradictory, as it was reported to be much less effective These results lend support to the existence of a critical link between the Trp metabolism in the blood and neurodegeneration, and provide a foundation for the treatment of neurodegenerative diseases.
The metabolic shift concept
Another pharmacological approach is the use of KP enzyme inhibitors (Table 2) .
Neuroprotection can be achieved by making a metabolic shift towards the neuroprotective KYNA instead of the neurotoxic 3HK, 3HAA and QUIN 55 .
During the past two decades, many novel enzyme inhibitors have been developed which target KMO, kynureninase and 3HAO (Table 2 ) to attain this metabolic shift 55 .
The early attempts were made with compounds that proved to be non-selective inhibitors, e.g.
nicotinylalanine, but the later work was successful and combined therapy with prodrugs or analogues is now available 
Possibilities in nanotechnology
The development of nanotechnology-based carrier systems offers novel promising technology for drug delivery into the brain 260 . Through the use of these carriers, therapeutic drug levels may be achieved in the brain, even for drugs which would otherwise not reach the CNS. This approach has been investigated to facilitate KYNA delivery into the brain by preparing micelles as nanoscale containers 261 : non-ionic surfactants were used to deliver KYNA, the central effects of which were proved in in vivo studies after peripheral administration too.
However, further research is needed to develop biodegradable, biocompatible and non-toxic nanocarrier systems capable of promoting drug delivery into the brain without causing permanent damage to the BBB integrity. This review has focused not only on the the linkage between neurological diseases and the KP, but also on the normal aging process. Continued exploration of the differences between normal aging and late-onset neurodegenerative disorders may promote a better understanding of both processes.
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